Liquidia Technologies is a late-stage clinical biopharmaceutical company specializing in the development and commercialization of therapeutics using its proprietary PRINT technology. This technology allows for the precise engineering of drug particles, which aims to improve the safety, efficacy, and performance of a wide range of therapies while reducing manufacturing complexity and cost. Liquidia is currently focused on two primary product candidates: LIQ861, designed for the treatment of pulmonary arterial hypertension, and LIQ865, aimed at managing local post-operative pain. The company operates in the biopharmaceutical market, primarily serving patients with specific medical conditions that require advanced therapeutic solutions. Liquidia's business model revolves around the development, clinical testing, and eventual commercialization of its drug candidates. Revenue is generated through the sale of these therapeutics once they receive regulatory approval and are brought to market. The company also engages in public offerings of common stock to fund its operations and research initiatives.

Keywords: PRINT technology, drug particles, pulmonary arterial hypertension, post-operative pain, biopharmaceutical, clinical development, therapeutics, commercialization, patient safety, efficacy.